Literature DB >> 3276522

Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins.

Y Endo1, K Tsurugi, T Yutsudo, Y Takeda, T Ogasawara, K Igarashi.   

Abstract

The site of action of a Vero toxin (VT2 or Shiga-like toxin II) from enterohemorrhagic Escherichia coli and Shiga toxin from Shigella dysenteriae 1 on eukaryotic ribosomes was studied. Treatment of eukaryotic ribosomes with either toxin caused the release of a fragment of 400 nucleotides from 28S ribosomal RNA when the isolated ribosomal RNA was treated with aniline. Release of this fragment with aniline treatment was accompanied by inhibition of protein synthesis and of elongation-factor-1-dependent aminoacyl-tRNA binding to ribosomes. Analysis of the nucleotide sequence of the 3'-terminal fragment of 553 nucleotides of 28S rRNA of rat liver 60S ribosomal subunits suggested that an adenine base at position 4324 (A-4324) was absent in toxin-treated 28S rRNA. Further analysis by thin-layer chromatography demonstrated quantitative release of adenine from rat liver ribosomes on treatment with the toxins. These results indicate that both VT2 and Shiga toxin inactivate 60S ribosomal subunits by cleaving the N-glycosidic bond at A-4324 in 28S ribosomal RNA.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3276522     DOI: 10.1111/j.1432-1033.1988.tb13756.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  284 in total

1.  Shiga toxins 1 and 2 translocate differently across polarized intestinal epithelial cells.

Authors:  B P Hurley; M Jacewicz; C M Thorpe; L L Lincicome; A J King; G T Keusch; D W Acheson
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

Review 2.  Shiga toxin-associated hemolytic uremic syndrome: advances in pathogenesis and therapeutics.

Authors:  Tania N Petruzziello-Pellegrini; Philip A Marsden
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-07       Impact factor: 2.894

3.  Toxin production by Campylobacter spp.

Authors:  T M Wassenaar
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

4.  Adenovirus vector expressing Stx1/Stx2-neutralizing agent protects piglets infected with Escherichia coli O157:H7 against fatal systemic intoxication.

Authors:  Abhineet S Sheoran; Igor P Dmitriev; Elena A Kashentseva; Ocean Cohen; Jean Mukherjee; Michelle Debatis; Jonathan Shearer; Jacqueline M Tremblay; Gillian Beamer; David T Curiel; Charles B Shoemaker; Saul Tzipori
Journal:  Infect Immun       Date:  2014-11-03       Impact factor: 3.441

5.  Induction of verotoxin sensitivity in receptor-deficient cell lines using the receptor glycolipid globotriosylceramide.

Authors:  T Waddell; A Cohen; C A Lingwood
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

6.  Participation of the syntaxin 5/Ykt6/GS28/GS15 SNARE complex in transport from the early/recycling endosome to the trans-Golgi network.

Authors:  Guihua Tai; Lei Lu; Tuan Lao Wang; Bor Luen Tang; Bruno Goud; Ludger Johannes; Wanjin Hong
Journal:  Mol Biol Cell       Date:  2004-06-23       Impact factor: 4.138

7.  A cycling cis-Golgi protein mediates endosome-to-Golgi traffic.

Authors:  Rajalaxmi Natarajan; Adam D Linstedt
Journal:  Mol Biol Cell       Date:  2004-08-25       Impact factor: 4.138

Review 8.  New insights into the haemolytic uraemic syndromes.

Authors:  D V Milford; C M Taylor
Journal:  Arch Dis Child       Date:  1990-07       Impact factor: 3.791

Review 9.  Shiga toxin triggers endothelial and podocyte injury: the role of complement activation.

Authors:  Carlamaria Zoja; Simona Buelli; Marina Morigi
Journal:  Pediatr Nephrol       Date:  2017-12-06       Impact factor: 3.714

10.  Protection by a recombinant Mycobacterium bovis Bacillus Calmette-Guerin vaccine expressing Shiga toxin 2 B subunit against Shiga toxin-producing Escherichia coli in mice.

Authors:  Jun Fujii; Mariko Naito; Takashi Yutsudo; Sohkichi Matsumoto; Daniel P Heatherly; Takeshi Yamada; Hideyuki Kobayashi; Shin-Ichi Yoshida; Tom Obrig
Journal:  Clin Vaccine Immunol       Date:  2012-10-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.